1Freid VM,Makuc DM,Rooks RN.Ambulatory health care visitsby children:principal diagnosis and place of visit[J].Vi.tal Health Stat,1998,137:1.

2Faden H,Duffy L,Boeve M.Otitis media:backto basics[J].Pediatr Infect Dis J,1998,17:1105.

3Bluestone CD,Stephenson JS,Martin LM.Ten years review of otitis media pathogen[J].Pediatr Infect Ids J,1992,118(supple):7.

4刘有宁,佘丹阳.我国下呼吸道感染治病院的构成、耐药特点及治疗策略[J].中国抗菌药物临床安全应用论坛,2005,2:16.

5Butler JC,Brei man RF,Campbell JF,et,al.Polysaccharide pneumococcal vaccine efficacy:an evaluation of current recom.mendations[J].JAMA,1993,270:1826.

6Austrian R,Gold J.Pneumococcal bacteremia with especial re.ference to bacteremic pneumococcal pneumonia[J].Ann Intern Med,1964,60:759.

7Austrian R,Douglas RM,Schiff man G,et al.Prevention of pneumococcal pneumonia by vaccination[J].Trans Assoc Am Physicians,1976,89:184.

8Cowan MK,Ammann AJ,Wara DW,et al.Pneumococcal poly.saccharide i mmunizationininfants and children[J].Pediatrics,1978,62:721.

9杨耀,栗克喜,宋绍忠,等.23价肺炎球菌多糖疫苗临床试验[J].预防医学情报杂志,2007,23:390.

10Fedson DS.Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries:another view of the e.vidence[J].The Lancet Infectious Diseases,2003,3:272

11Koskela M,Leinonen M,Haiva VM,et al.First and second dose antibody responses to pneumococcal polysaccharide vac.cine ininfants[J].Pediatr Infect Dis,1986,5:45.

12American Academy of Pediatrics,Committee on Infectious Diseases.Policy statement:recommendations for the preven.tion of pneumococcal infections,includingthe use of pneumo.coccal conjugate vaccine(Prevnar),pneumococcal polysac.charide vaccine,and antibiotic prophylaxis[J].Pediatrics,2000,106:362.

13Black S,Shinefield H,Fireman B,et al.Efficacy,safety and i mmunogenicity of heptavalent pneumococcal conjugate vac.cine in children.Northern california kaiser permanente vac.cine study center group[J].Pediatr Infect Dis J,2000,19:187.

14Veenhoven R,Bogaert D,Uiterwaal C,et al.Effect of conju.gate pneumococcal vaccine followed by polysaccharide pneu.mococcal vaccine on recurrent acute otitis media:a randomised study[J].Lancet,2003,361:2189.

15Casey JR,Pichichero ME.Changes in frequency and patho.gens causing acute otits media in1995～2003[J].Pedatr In.fect Dis,2004,23:824.

16Eskola J,Kilpi T,Pal mu A,et al.Efficacy of a pneumococcal conjugate vaccine against acute otitis media[J].N Engl J Med,2001,344:403.

17Marsh RL,Smith.Vaughan H,Beissbarth J,et al.Molecu.lar characterisation of pneumococcal serotype16F:Estab.lished predominant carriage and otitis media serotype in the7vPCVera[J].Vaccine,2007,25:2434.

18Pelton SI,Dagan R,Gaines BM,et al.Pneumococcal conju.gate vaccines:proceedings froman Interactive Symposiumat the41st Interscience.Conference on anti microbial agents and chemotherapy[J].Vaccine,2003,21:1562.

19Zhang Q,Choo S,Finn A.I mmune responses to novel pneumococcal proteins pneumolysin,PspA,PsaA,and CbpA in adenoidal B cells from children[J].Infect I mmun,2002,70:5363.

20McDaniel LS,Sheffield JS,Delucchi P,et al.PspA,a surface protein of streptococcus pneumoniae,is capable of eliciting protection against pneumococci of more than one capsular type[J].Infect I mmun,1991,59:222.

21Nabors GS,Braun PA,Herrmann DJ,et al.I mmunization of healthy adults with a single recombinant pneumococcal sur.face protein A(PspA)variant sti mulates broadly cross.reac.tive antiboides to heterologous PspA molecules[J].Vaccine,2000,18:1743.

22Crain MJ,Walt man WD,Turner JS,et al.Pneumococcal surface protein A(PspA)is serologically highly variable and is expressed by all clinically i mportant capsular serotypes of Streptococcus pneumoniae[J].Infect I mmun,1990,58:3293.

23Brooks.Walter A,Briles DE,Hollingshead SK.The pspC gene of Streptococcus pneumoniae encodes a polymorphic pro.tein,PspC,which elicits cross.reactive antibodies to PspA and provides i mmunity to pneumococcal bacteremia[J].In.fect I mmun,1999,67:6533.

24Kadioglu A,Coward W,Colston MJ,et al.CD4.T.1lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneu.mococcal infection[J].Infect I mmun,2004,72:2689.

25Briles DE,Ades E,Paton JC,et al.Intranasal i mmunization of mice with a mixture of the pneumococcal proteins PsaAand PspAis highly protective against nasopharyngeal carriage of Streptococcus pneumoniae[J].Infect I mmun,2000,68:796.

26Tai SS.Streptococcus pneumoniae protein vaccine candi.dates:properties,activities and ani mal studies[J].Crit RevMicrobiol,2006,32:139.

27陈兵,戴文佳,王正敏,等基因工程技术制备中耳炎新型蛋白载体[J].中华耳鼻咽喉头颈外科杂志,2006,41:570

28陈泽宇,陈兵,王正敏,等肺炎球菌荚膜多糖和溶血素结合疫苗的制备及其免疫原性研究[J].中华微生物和免疫学杂志,2006,26:906.

29Johnson SE,Dykes JK,Jue DL,et al.Inhibition of pneumo.coccal carriage in mice by subcutaneous i mmunization with peptides fromthe common surface protein pneumococcal sur.face adhesina[J].Infect Dis,2002,185:489.

30Seo JY,Seong SY,Ahn BY,et al.Crossprotective i mmunity of mice induced by oral i mmunization with pneumococcal sur.face adhesin a encapsulated in microspheres[J].Infect I m.mun,2002,70:1143.

31Rapola S,Jantti V,Eerola M,et al.Anti.PsaAand the risk of pneumococcal AOMand carriagev[J].Vaccine,2003,21:3608.

32Ogunniyi AD,Folland RL,Briles DE,et,al.I mmunization of mice with combinationsof pneumococcal virulence proteins e.licits enhanced protection against challenge with Streptococ.cus pneumoniae[J].Infect I mmun,2000,68:3028.

33Rappuoli R.Reverse vaccinology[J].Curr Opin Microbiol,2000,3:445.

34Whalen RG.DNAvaccines for emerging infectious diseases:what if[J].Emerging Infect Dis,1996,2:168.

35McDaniel LS,Loechel F,Benedict C,et al.I mmunization with a plasmid expressing pneumococcal surface protein A(PspA)can elicit protection against fatal infection with Strep.tococcus pneumoniae[J].Gene Ther,1997,4:375.

36Miyaji EN,Dias WO,Tanizaki MM,et al Protective efficacy of pspA(pneumococcal surface protein A).based DNAvac.cines:contribution of both humoral and cellular i mmune re.sponses[J].FEMS I mmunology&Medical Microbiology,2003:37,53.

37Lee CJ,Li ZM.Protective i mmunity and gene expression re.lated to pneumococcal glycoconjugate[J].Advancesin Experi.mental Medicine&Biology,2001,491:505.

38Ferreira DM,Miyaji EN,Oliveira ML,et al.DNAvaccines expressing pneumococcal surface protein A(PspA)elicit pro.tection levels comparable to recombinant protein[J].J Med Microbiol,2006,55:375.